Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

Second-generation DAAs for HCV: real-life efficacy in the resist-HCV cohort

Irene Cacciola,Salvatore Petta,Vincenza Calvaruso,Marco Distefano,Gaetano Scifo,Francesco Di Lorenzo,Adriana Sanfilippo,Maria Antonietta Di Rosolini,Antonio Davì,Francesco Benanti,Bruno Cacopardo,Anna Licata,Lydia Giannitrapani,Maria Rita Cannavò,Maurizio Russello,Salvatore Madonia,Maria Grazia Bavetta,Antonio Digiacomo,Alfonso Averna, Licia Nunzia La Rocca,Gaetano Bertino,Fabrizio Bronte,Luigi Guarneri,Ignazio Scalisi,Carmelo Iacobello,Pietro Colletti,Fabio Cartabellotta,Giuseppe Alaimo, Portelli Vincenzo,Teresa Pollicino,Francesca Ceccherini Silberstein,Giovanni Squadrito,Giovanni Raimondo,Antonio Craxi,Vito Di Marco

Digestive and Liver Disease（2020）

Cited 0|Views57
No score
Abstract
Background and aims: RESIST-HCV (Rete Sicilia Selezione Terapia – HCV) registers all patients in Sicily with chronic HCV infection treated with DAAs, allowing a real-time measure of their efficacy in practice. This analysis aims to evaluate second-generation regimens (Sofosbuvir plus Velpatasvir: SOF/VEL; Glecaprevir plus Pibrentasvir: GLE/PIB;Elbasvir/Grazoprevir: EBV/GRZ), in order to evaluate SVR rates of DAA-naïve patients to currently available regimens.
More
Translated text
Key words
second-generation,real-life,resist-hcv
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined